Generic placeholder image

Recent Patents on Cardiovascular Drug Discovery


ISSN (Print): 2212-3962
ISSN (Online): 1574-8901

A3 Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes

Author(s): Shamama Nishat, Hiba Shabir, Asfar S. Azmi and Habib R. Ansari

Volume 7, Issue 1, 2012

Page: [59 - 70] Pages: 12

DOI: 10.2174/157489012799362421

Price: $65


Diabetes mellitus categorized as type I and II, is a disease of pancreatic insulin, affecting blood glucose level in the body. Recent evidence suggests that cardiac diseases such as hypertension, coronary artery disease, congestive heart failure, and diabetic cardiomyopathy are associated with diabetes and hyperglycemia. The adenosine receptors (AR) have been reported to play an important role in the regulation of these diseases. Four adenosine receptors have been cloned and characterized from several different mammalian species. The receptors are named adenosine A1, A2A, A2B, and A3. The A2A and A2B receptors preferably interact with members of the Gs family of G proteins and the A1 and A3 receptors with Gi/o proteins. The ubiquitous levels of adenosine are found in each cell in normal conditions but in disease conditions its level has been shown to increase and activate G-protein mediated signaling pathway leading to artery constriction in cardiovascular diseases and diabetes. Various studies have demonstrated that A3AR is a potent cardioprotectant during myocardial ischemeia/ischemic reperfusion. Role of A3AR receptor as a possible cardioprotectant in diabetes is under investigation and studies have verified the involvement of cyclooxygenases (COXs) and NADPH oxidase pathways. This review summarizes the possible role of A3AR in cardiovascular disease and discusses advancement in the development of therapeutic agents targeting cardioprotection with discussion on recent patents on A3 agonists that are being utilized in the clinical setting. We anticipate that detailed pharmacological studies of adenosine A3 receptors could help in understanding the link between cardiovascular disease and diabetes and this can be utilized to develop newer therapies that selectively target A3 receptor to overcome cardiac challenges.

Keywords: A3 Adenosine receptor, cardiovascular complications, diabetes, heart, SMOOTH MUSCLE CELL PROLIFERATION, CALCIUM SIGNALING, A3 agonist, A3 RECEPTOR AGONISTS, dendrimer conjugates, purine derivatives

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy